News | Structural Heart Occluders | February 15, 2017

UAB First in Alabama to Implement New FDA-Approved Amplatzer PFO Occluder

Device reduces risk of recurrent ischemic stroke for 25 to 30 percent of Americans who have a patent foramen ovale

University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation

February 15, 2017 — Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-approved patent foramen ovale occluder in Alabama. 

A PFO is a hole in the heart that does not close the way it should after birth. During fetal development, a small flap-like opening — the foramen ovale — is normally present in the wall between the right and left upper chambers of the heart. It normally closes during infancy. With the new Amplatzer PFO Occluder, ischemic stroke patients will now have access to a closure device shown to reduce risk of recurrent stroke, rather than relying on medical management alone. 

Baker-Dean Endowed Professor in Interventional Cardiology Massoud Leesar, M.D., performed the first procedure Jan. 25, 2017. 

“This new device has the potential to help many patients who suffer from PFO and stroke,” he said. “Our first patient did very well and was discharged the day after the procedure since the echocardiogram showed complete closure of PFO.” 

Approximately 25 to 30 percent of Americans have a PFO, which typically causes no health problems and does not require treatment. The cause of most strokes can be identified, such as poorly controlled high blood pressure, narrowed blood vessels due to cholesterol deposits and scar tissue (atherosclerosis), or a blood clot caused by an abnormal heart rhythm (atrial fibrillation).

“Stroke in patients younger than 60 years old is most likely related to PFO,” Leesar said. “In patients older than 60, other causes such as atherosclerosis and atrial fibrillation will need to be ruled out. These patients are typically referred by neurologists who cannot define other causes for stroke.” 

The Amplatzer PFO Occluder is inserted through a catheter that is placed in a leg vein and advanced to the heart. It is then implanted close to the hole in the heart between the right atrium and the left chamber. The procedure is minimally invasive, and recovery time is minimal.

Nearly 795,000 new or recurrent strokes occur every year in the United States, making it the fifth-leading cause of death and leading cause of serious long-term disability for Americans, according to the American Heart Association. Ischemic strokes account for 87 percent of strokes, and occur when a blood vessel is obstructed, depleting the brain of its blood supply.

The Amplatzer PFO Occluder is developed by St. Jude Medical Inc.

For more information: www.sjm.com 

Related Content

Technology | Pulmonary Embolism| March 01, 2017
March 1, 2017 — BTG plc announced U.S.
Abiomed, Impella heart pump, 50,000 patients treated, United States, milestone
News | Ventricular Assist Devices (VAD)| February 24, 2017
Abiomed Inc. announced that it has supported more than 50,000 patients in the U.S. with its Impella line of heart pumps...
Children's Hospital Los Angeles, CHLA, Frank Ing, 3-D printed model, pulmonary artery

Pediatric interventional cardiologist Frank Ing, M.D., chief of the Division of Cardiology and co-director of the Heart Institute at Children’s Hospital Los Angeles. Photo courtesy of Children's Hospital Los Angeles.

Feature | 3-D Printing| February 22, 2017
When Children’s Hospital Los Angeles cardiologists found evidence that a portion of Nate Yamane’s pulmonary artery they...
coordinated heart attack care, Ontario STEMI Bypass Protocol, Canada
News | Cath Lab| February 22, 2017
Two new Ontario-wide heart attack protocols for paramedic services and emergency departments that aim to saves lives...
transradial approach, same-day cardiac procedures, radial access, $300 million annual savings, JACC Cardiovascular Interventions study
News | Radial Access| February 22, 2017
If hospitals can perform more transradial, same-day percutaneous coronary intervention (PCI), hospitals across the U.S...
Technology | Radial Access| February 17, 2017
Medtronic plc announced that its coronary portfolio will now include the DxTerity Diagnostic Angiography Catheter line...
Sponsored Content | Videos | Inventory Management| February 17, 2017
The supplies you use in your cath lab are complex and very valuable.
pregnant women, congenital heart disease, new recommendations, Circulation journal, UCLA
News | Womens Healthcare| February 16, 2017
February 16, 2017 — New recommendations for healthcare providers, published in the American Heart Association journal
Edwards Intuity Elite sutureless aortic valve, first implants in Connecticut, WCHN, Western Connecticut Health Network
News | Cardiovascular Surgery| February 16, 2017
Western Connecticut Health Network (WCHN) cardiothoracic surgeons Cary Passik, M.D., and Robert Gallagher, M.D., were...
Overlay Init